Form D · Biotechnology
Kubanda Cryotherapy, Inc.
Baltimore, MD · CIK 0001853949
Offering snapshot reported Apr 25, 2024 · SEC filing
- Reported sold
- $200K Offering amount: $200K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $200K Reported outside-investor minimum
- First sale
- Apr 22, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 25, 2024 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Apr 17, 2024 | Initial | $725,000 | No comparison | 15 | SEC filing |
| Apr 2, 2021 | Initial | $100,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-511528
Convertible Note convertible into preferred stock
Source: Form D, filed Apr 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Yixin Hu | Director, Executive |
| Bailey Surtees | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3600 Clipper Mill Road Suite 310
Baltimore, MD, 21202
Baltimore, MD, 21202